{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:37:01Z","timestamp":1790617021090,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiol med"],"DOI":"10.1007\/s11547-025-02069-w","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T14:48:27Z","timestamp":1754491707000},"page":"1888-1896","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Conventional vs. DEB vs. DSM: Which technique for palliative TACE in intermediate-stage HCC? Results on 70 patients in terms of efficacy and tolerance"],"prefix":"10.1007","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9080-8833","authenticated-orcid":false,"given":"Francesco","family":"Giurazza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Carrubba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Punzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Guarracino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella","family":"Brangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Falaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Migliaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Corvino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Vennarecci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Giovanni","family":"Di Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Niola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"2069_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1148\/radiology.148.2.6306721","volume":"148","author":"R Yamada","year":"1983","unstructured":"Yamada R, Sato M, Kawabata M et al (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148:397\u2013401","journal-title":"Radiology"},{"key":"2069_CR2","doi-asserted-by":"crossref","unstructured":"Llovet JM, Real MI, Monta\u00f1a X, et al. Barcelona Liver Cancer Group (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319):1734\u20131739","DOI":"10.1016\/S0140-6736(02)08649-X"},{"issue":"5","key":"2069_CR3","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"CM Lo","year":"2002","unstructured":"Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5):1164\u20131171","journal-title":"Hepatology"},{"key":"2069_CR4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ctrv.2018.11.002","volume":"72","author":"JL Raoul","year":"2019","unstructured":"Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T (2019) Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev 72:28\u201336","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"2069_CR5","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s00270-012-0476-z","volume":"36","author":"T Irie","year":"2013","unstructured":"Irie T, Kuramochi M, Takahashi N (2013) Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: measurement of balloon-occluded arterial stump pressure. Cardiovasc Intervent Radiol 36(3):706\u2013713","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"12","key":"2069_CR6","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1007\/s00270-021-02968-1","volume":"44","author":"P Lucatelli","year":"2021","unstructured":"Lucatelli P, Burrel M, Guiu B, de Rubeis G, van Delden O, Helmberger T (2021) CIRSE standards of practice on hepatic transarterial chemoembolisation. Cardiovasc Intervent Radiol 44(12):1851\u20131867","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2069_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","volume":"33","author":"J Lammer","year":"2010","unstructured":"Lammer J, Malagari K, Vogl T et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41\u201352","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2069_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/bjc.2014.199","volume":"111","author":"R Golfieri","year":"2014","unstructured":"Golfieri R, Giampalma E, Renzulli M et al (2014) Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 111:255\u2013264","journal-title":"Br J Cancer"},{"key":"2069_CR9","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.dld.2016.02.005","volume":"48","author":"A Facciorusso","year":"2016","unstructured":"Facciorusso A, Di Maso M, Muscatiello N (2016) Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis. Dig Liver Dis 48:571\u2013577","journal-title":"Dig Liver Dis"},{"issue":"7","key":"2069_CR10","doi-asserted-by":"publisher","first-page":"e0133488","DOI":"10.1371\/journal.pone.0133488","volume":"10","author":"B Vincenzi","year":"2015","unstructured":"Vincenzi B, Di Maio M, Silletta M et al (2015) Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based meta-analysis. PLoS ONE 10(7):e0133488","journal-title":"PLoS ONE"},{"issue":"Suppl(0)","key":"2069_CR11","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1097\/MCG.0b013e3182872f29","volume":"47","author":"S Mittal","year":"2013","unstructured":"Mittal S, El-Serag HB (2013) Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 47(Suppl(0)):S2-6","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"2069_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver (2025) EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol 82(2):315\u2013374","journal-title":"J Hepatol"},{"issue":"1","key":"2069_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52\u201360","journal-title":"Semin Liver Dis"},{"issue":"6","key":"2069_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jvir.2012.02.012","volume":"23","author":"IJ Patel","year":"2012","unstructured":"Patel IJ, Davidson JC, Nikolic B et al (2012) Standards of Practice Committee, with Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Endorsement. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol 23(6):727\u2013736","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"2069_CR15","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00270-020-02763-4","volume":"44","author":"M Hadi","year":"2021","unstructured":"Hadi M, Walker C, Desborough M et al (2021) CIRSE standards of practice on peri-operative anticoagulation management during interventional radiology procedures. Cardiovasc Intervent Radiol 44(4):523\u2013536","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"12","key":"2069_CR16","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1007\/s11547-024-01906-8","volume":"129","author":"F Giurazza","year":"2024","unstructured":"Giurazza F, Vizzuso A, Capussela T et al (2024) Left radial vs right femoral: comparison between arterial accesses in c-TACE procedures in terms of operator radiations exposure and patient comfort. Radiol Med 129(12):1936\u20132194","journal-title":"Radiol Med"},{"issue":"10","key":"2069_CR17","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1007\/s00270-022-03233-9","volume":"45","author":"T de Baere","year":"2022","unstructured":"de Baere T, Ronot M, Chung JW et al (2022) Initiative on superselective conventional transarterial chemoembolization results (INSPIRE). Cardiovasc Intervent Radiol 45(10):1430\u20131440","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"8","key":"2069_CR18","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00270-017-1703-4","volume":"40","author":"DK Filippiadis","year":"2017","unstructured":"Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL (2017) Cirse quality assurance document and standards for classification of complications: the Cirse classification system. Cardiovasc Intervent Radiol 40(8):1141\u20131146","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"5","key":"2069_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00432-024-05722-5","volume":"150","author":"P Schindler","year":"2024","unstructured":"Schindler P, Kaldewey D, Rennebaum F et al (2024) Safety, efficacy, and survival of different transarterial chemoembolization techniques in the management of unresectable hepatocellular carcinoma: a comparative single-center analysis. J Cancer Res Clin Oncol 150(5):235","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"2069_CR20","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1007\/s00432-021-03900-3","volume":"148","author":"I Mohr","year":"2022","unstructured":"Mohr I, Vogeler M, Pfeiffenberger J et al (2022) Clinical effects and safety of different transarterial chemoembolization methods for bridging and palliative treatments in hepatocellular carcinoma. J Cancer Res Clin Oncol 148(11):3163\u20133174","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"2069_CR21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.14218\/JCTH.2016.00058","volume":"4","author":"A Schicho","year":"2016","unstructured":"Schicho A, Hellerbrand C, Kr\u00fcger K et al (2016) Impact of different embolic agents for transarterial chemoembolization (TACE) procedures on systemic vascular endothelial growth factor (VEGF) Levels. J Clin Transl Hepatol 4(4):288\u2013292","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"2069_CR22","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1186\/s12885-019-5989-2","volume":"19","author":"RA Miksad","year":"2019","unstructured":"Miksad RA, Ogasawara S, Xia F, Fellous M, Piscaglia F (2019) Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study. BMC Cancer 19(1):795","journal-title":"BMC Cancer"},{"key":"2069_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-024-11272-8","author":"F Collettini","year":"2024","unstructured":"Collettini F, Andra\u0161ina T, Reimer P et al (2024) Degradable starch microspheres transarterial chemoembolization (DSM-TACE) in patients with unresectable hepatocellular carcinoma: results from the prospective multicenter observational HepaStar Trial. Eur Radiol. https:\/\/doi.org\/10.1007\/s00330-024-11272-8","journal-title":"Eur Radiol"},{"issue":"9","key":"2069_CR24","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1055\/a-1111-9955","volume":"192","author":"J Haubold","year":"2020","unstructured":"Haubold J, Reinboldt MP, Wetter A et al (2020) DSM-TACE of HCC: evaluation of tumor response in patients ineligible for other systemic or loco-regional therapies. Rofo 192(9):862\u2013869","journal-title":"Rofo"},{"issue":"20","key":"2069_CR25","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.3390\/cancers13205122","volume":"13","author":"JM Ludwig","year":"2021","unstructured":"Ludwig JM, Iezzi R, Theysohn JM, Albrecht T, Posa A, Gross A (2021) European multicenter study on degradable starch microsphere TACE: the digestible way to conquer HCC in patients with high tumor burden. Cancers (Basel). 13(20):5122","journal-title":"Cancers (Basel)."},{"issue":"3","key":"2069_CR26","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00330-018-5692-8","volume":"29","author":"R Iezzi","year":"2019","unstructured":"Iezzi R, Pompili M, Rinninella E et al (2019) TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib. Eur Radiol 29(3):1285\u20131292","journal-title":"Eur Radiol"},{"issue":"3","key":"2069_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s00270-019-02364-w","volume":"43","author":"A Gross","year":"2020","unstructured":"Gross A, Albrecht T (2020) Transarterial chemoembolisation (TACE) with degradable starch microspheres (DSM) and anthracycline in patients with locally extensive hepatocellular carcinoma (HCC): safety and efficacy. Cardiovasc Intervent Radiol 43(3):402\u2013410","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"12","key":"2069_CR28","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.4254\/wjh.v7.i12.1694","volume":"7","author":"A Orlacchio","year":"2015","unstructured":"Orlacchio A, Chegai F, Merolla S et al (2015) Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: Strategies using degradable starch microspheres transcatheter arterial chemo-embolization. World J Hepatol 7(12):1694\u20131700","journal-title":"World J Hepatol"},{"issue":"2","key":"2069_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/01.COC.0000018174.53573.67","volume":"26","author":"J Furuse","year":"2003","unstructured":"Furuse J, Ishii H, Satake M et al (2003) Pilot study of transcatheter arterial chemoembolization with degradable starch microspheres in patients with hepatocellular carcinoma. Am J Clin Oncol 26(2):159\u2013164","journal-title":"Am J Clin Oncol"}],"container-title":["La radiologia medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-025-02069-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11547-025-02069-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-025-02069-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:13:18Z","timestamp":1762884798000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11547-025-02069-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["2069"],"URL":"https:\/\/doi.org\/10.1007\/s11547-025-02069-w","relation":{},"ISSN":["1826-6983"],"issn-type":[{"value":"1826-6983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients gave written informed consent to participate in the study and data analysis; all written consents are available in the archives of Vascular and Interventional Radiology Dept of Cardarelli Hospital of Naples.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All patients gave written informed consent for data publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The study adhered to the principles of the Declarations of Helsinki and Istanbul. The study was approved by the ethical review board (DEL:233\/2024) considering its prospective design.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Research participants"}},{"value":"Informed consent was obtained from all patients included in the study, if clinical conditions allowed.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}